Actavis Confirms District Court Ruling In Generic Rapamune® Patent Suit

   Actavis Confirms District Court Ruling In Generic Rapamune® Patent Suit

PR Newswire

PARSIPPANY, N.J., Jan. 31, 2013

PARSIPPANY, N.J., Jan.31, 2013 /PRNewswire/ --Actavis, Inc. (NYSE: ACT)
today confirmed that the United States District Court for the District of
Delaware has found United States Patent No. 5,100,899 (the '899 Patent) valid
and infringed by Actavis' generic version of Pfizer Inc.'s Rapamune®
(sirolimus). The Company said that it was reviewing the court's decision and
would evaluate all available options, including an appeal.

Rapamune® tablets are indicated for the prophylaxis of organ rejection in
patients aged 13 years or older receiving renal transplants. Actavis'
Abbreviated New Drug Application ("ANDA") for its generic version of Rapamune®
has not yet received tentative or final approval from the U.S. Food and Drug

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand
and biosimilar products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and international headquarters in Zug,

Actavis is the world's third-largest generics prescription drug manufacturer.
Operating as Actavis Pharma, the Company develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries. The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33 global
markets. Actavis Pharma also develops and out-licenses generic pharmaceutical
products outside the U.S. through its Medis third-party business, the world's
largest generic pharmaceutical out-licensing business. Medis has more than 300
customers globally, and offers a broad portfolio of more than 200 products.

Actavis Specialty Brands is the Company's global branded specialty
pharmaceutical business, which develops and markets a portfolio of
approximately 40 products principally in the United States and Canada that are
focused in the Urology and Women's Health therapeutic categories. Actavis
Specialty Brands is committed to developing and marketing biosimilars products
in Women's Health, Oncology and other therapeutic categories, and currently
has a portfolio of 5 biosimilar products in development. 

Actavis Global Operations has more than 30 manufacturing and distribution
facilities around the world, with a capacity of approximately 44 billion units
annually. Actavis Global Operations also includes Anda, Inc., the
fourth-largest U.S. generic pharmaceutical product distributor in the United

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actual results may differ materially from Actavis' current
expectations depending upon a number of factors, risks and uncertainties
affecting Actavis' business. These factors include, among others; the
difficulty of predicting the timing and outcome of any appeal of the pending
patent litigation; the difficulty of predicting the timing or outcome of
product development efforts, including FDA and other regulatory agency
approvals and actions, if any; the impact of competitive products and pricing;
the timing and success of product launches; difficulties or delays in
manufacturing; the availability and pricing of third party sourced products
and materials; successful compliance with FDA and other governmental
regulations applicable to Actavis and its third party manufacturers'
facilities, products and/or businesses; changes in the laws and regulations;
and such other risks and uncertainties detailed in Actavis' periodic public
filings with the Securities and Exchange Commission, including but not limited
to Actavis' Annual Report on form 10-K for the year ended December 31, 2011
and its Quarterly Report on Form 10-Q for the period ended September 30, 2012
(such periodic public filings having been filed under the "Watson
Pharmaceuticals, Inc." name). Except as expressly required by law, Actavis
disclaims any intent or obligation to update these forward-looking statements.

Rapamune^® is a registered trademark of Pfizer Inc.

CONTACTS: Investors:
          Lisa DeFrancesco
          (862) 261-7152
          Charlie Mayr
          (862) 261-8030

(Logo: )

SOURCE Actavis, Inc.

Press spacebar to pause and continue. Press esc to stop.